- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] PO394: GA in the Canadian Treat & Extend Trial With Ranibizumab in Patients With nAMD (CANTREAT) () - Nov 11, 2020 - Abstract #AAO2020AAO_685;
P=N/A
Mean change in square-root area of GA from baseline in the OM and T&E arms was 243.70 μm and 340.56 μm at 12 months (P = .59), 342.62 μm and 415.04 μm at 24 months (P = .69) and 1,003.27 μm and 1,374.61 μm at 36 months (P = .88), respectively, using a two-tailed unequal variance t test. Conclusion New or progressive GA was detected with similar frequency, type and surface area in both OM and T&E arms of the CANTREAT study at 12, 24 and 36 months.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] PO152: The Association of POAG and OHT With Intravitreal Anti-VEGF () - Nov 11, 2020 - Abstract #AAO2020AAO_532;
Conclusions Patients treated with anti-VEGF agents against age-matched controls had an increased rate of POAG, OHT and GS. Interestingly, the rates of POAG and OHT were strongly correlated with the number of IVIs.
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] PO423: Visual Impact of Fluctuations in CST in nAMD Patients Treated with Anti-VEGF in VIEW () - Nov 11, 2020 - Abstract #AAO2020AAO_353;
Methods Standard deviation of each eye's CST from baseline through Week 52 was calculated as a measure of individual CST variability and evaluated as quartiles (Q1: ≤27.6 μm, n = 448; Q2: 27.6–42.5 μm, n = 448; Q3: 42.5–65.3 μm, n = 448; Q4: >65.3 μm, n = 448) for eyes that received ranibizumab 0.5 mg every 4 weeks (Rq4) or intravitreal aflibercept injection 2 mg every 4 weeks (2q4) or every 8 weeks (after three monthly doses; 2q8) through Week 52 in VIEW...Conclusion The highest CST fluctuation was associated with lower BCVA gain. BCVA gain with each treatment was similar within each quartile of CST fluctuation.
- |||||||||| faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] PO388: Faricimab: Evidence for Differentiation With Dual Angiopoietin-2 (Ang-2)/VEGF-A Inhibition in DME and nAMD () - Nov 11, 2020 - Abstract #AAO2020AAO_344;
P2
In STAIRWAY, BCVA and macular anatomy improvements with faricimab dosed every 16 and 12 weeks were comparable to those with monthly ranibizumab. Conclusion Phase 2 and preclinical data support improved and sustained efficacy of faricimab through dual Ang-2/VEGF inhibition, likely secondary to vascular stabilization effects of simultaneous Ang-2/VEGF-A neutralization.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] PO418: Cost Utility of Anti-VEGF Treatment for Macular Edema Secondary to CRVO () - Nov 11, 2020 - Abstract #AAO2020AAO_334;
The incremental cost-effectiveness ratio (ICER) of IVA compared to IVB was $772,283 / QALY ($791,690 / QALY), IVR to IVB was $1,989,579 / QALY ($1,980,695 / QALY), while IVA to IVR was cost-effective (ICER < 0). Conclusion IVB maintains the best cost utility; IVA maintains acceptable lifetime cost / QALY, while having a favorable cost utility compared to IVR.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema. (Pubmed Central) - Nov 3, 2020
Two intravitreal ranibizumab injections had also been performed in both eyes of one patient...This case series demonstrated the potential efficacy of interferon alpha 2b in the treatment of refractory diabetic macular edema. It might be an option in patients with contraindications for intravitreal injections.
- |||||||||| LKA651 / Novartis, MorphoSys
Trial completion date, Trial primary completion date: Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Nov 1, 2020
P2, N=90, Recruiting,
Thus, switching therapy may be a safe and effective treatment for patients with refractory DME. Trial completion date: Feb 2021 --> Nov 2021 | Trial primary completion date: Feb 2021 --> Nov 2021
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Review, Journal, Real-World Evidence: Trends in Real-World Neovascular AMD Treatment Outcomes in the UK. (Pubmed Central) - Nov 1, 2020
Only ranibizumab and aflibercept outcome data were available...UK real-world outcomes have improved over the last decade with improved service delivery and the adoption of more proactive treatment regimens but are still not always as impressive as registration clinical trial results. Access to longer-acting anti-VEGF therapies would reduce the treatment burden for patients, carers, and the healthcare system, potentially making replication of clinical trial results possible in the NHS.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. (Pubmed Central) - Oct 31, 2020
One hundred treatment-naïve eyes of 100 patients with PCV treated for 24 months at Keio University Hospital with intravitreal ranibizumab or aflibercept monotherapy (three injections and PRN thereafter) were retrospectively analyzed...Mean CVD and CCT at remission were greater in patients with initial pachyvessels and pachychoroid than in those without; the basal levels of CVD and CCT most likely represent VEGF-unrelated conditions. CVD increase preceded CCT increase and recurrent exudative changes, suggesting that the VEGF-related CVD increase may regulate CCT and exudative change; and that CVD may be a biomarker of exudative change.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration. (Pubmed Central) - Oct 27, 2020
Most of the studies have focused on the extended in vitro release behaviour of the developed DDSs, but data as antibody bioactivity, biocompatibility or in vivo stability is sometimes scarce. Moreover, as DDS development relies on in vivo pharmacokinetic analyses to evaluate the extended drug release, all the information regarding anti-VEGF intravitreal pharmacokinetics in different animal species have been compiled.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. (Pubmed Central) - Oct 27, 2020
2020;57(1):61-66.]. In our small retrospective study, eyes switched to intravitreal aflibercept for persistent cystoid macular edema (CME) due to RVO improved vision and macular thickness; however, larger prospective studies are required to validate our findings.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab. (Pubmed Central) - Oct 25, 2020
Multivariate analysis revealed that smaller CSF thickness at baseline predicted the early remission of DME under PRN IVR injections (odds ratio, 0.989; 95% confidence interval, 0.982-0.997; P = 0.008). These data elucidate the clinical characteristics of early remission of DME under PRN IVR injections and suggest that smaller CSF thickness at baseline is a novel predictor of early remission under PRN IVR injections for DME.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Adventitial Fibroblast-derived VEGF Promotes Vasa Vasorum-associated Neointima Formation and Macrophage Recruitment. (Pubmed Central) - Oct 25, 2020
These data elucidate the clinical characteristics of early remission of DME under PRN IVR injections and suggest that smaller CSF thickness at baseline is a novel predictor of early remission under PRN IVR injections for DME. These results demonstrate that adventitial fibroblast-derived VEGF plays a significant role in the increase of vasa vasorum count which is involved in macrophage recruitment and neointima formation.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. (Pubmed Central) - Oct 22, 2020
We provide clinical suggestions for clinicians to both better manage patients receiving anti-VEGF agents intravitreally and detect any putative systemic renal effects of these agents. While acknowledging the risks of aberrant retinal angiogenesis, it is important for clinicians to be aware of the potential for adverse renal risks with use of these agents.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Circulating endothelial and progenitor cells in age-related macular degeneration. (Pubmed Central) - Oct 22, 2020
Anti-vascular endothelial growth factor treatment with intravitreal ranibizumab was associated with a significant reduction of endothelial progenitor cell levels, with no significant influence on circulating progenitor cells and circulating endothelial cells. We reported higher levels of circulating endothelial cells in age-related macular degeneration patients in comparison with the control group, thereby supporting the hypothesis of an involvement of endothelial dysregulation in the age-related macular degeneration and a reduction of the endothelial progenitor cell level in neovascular age-related macular degeneration patients after three intravitreal injections of ranibizumab.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Low Vision Rehabilitation: The Critical Role of Eccentric View Training in Improving Visual Function in the Setting Central Vision Loss (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_747;
Further instruction centers around stabilization and scanning techniquesEV training can be impacted by factors such as PRL size/quality, motivation, and cognitionDrastic improvement in functional visual acuity greatly improves ADLs performance and quality of life Treatment, Management Recommendations:Constant Wear SpectaclesSunwear SpectaclesDesktop Video MagnifierHand-Held MagnifierMonocular TelescopeSpectacle Mounted TelescopeBump Dots Conclusion ARMD can cause drastic changes in visual function related to VA, contrast, and glare.A comprehensive, low vision examination can uncover visual potential before the use of high magnification and build a stronger foundation for utilizing visual aids.It is crucial to establish, locate, and train a viable PRL as part of LVR in patients with central vision loss. Utilization of a PRL in such patients can maximize visual threshold and function thereby increasing one’s quality of life.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] A Spotlight on Differentials and Complications of Exudative Macular Degeneration (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_715;
Avastin is the best option for self-pay patients, however it is an off label anti-VEGF agent...Furethermore, it was found that dosing Lucentis as needed was equally effective to dosing monthly...The patient in this case called with a “grey spot” that then escalated to “black vision”. Even though CNVM is not an ocular emergency, this is considered an urgency and this patient received treatment quickly.
- |||||||||| faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Effect of Faricimab Treatment on Macular Anatomy in the STAIRWAY Trial in Neovascular Age-Related Macular Degeneration (nAMD) (Track II - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_560;
P2
Change from baseline in CNV component area across the treatment arms was –4.3, –5.6, and –4.8 mm2, respectively; change from baseline in neovascular leakage area was –4.6, –5.6, and –5.3 mm2. Vision and macular anatomy were maintained with approximately half as many injections on faricimab Q16W flex or Q12W fixed versus ranibizumab Q4W dosing regimen. Conclusion Preclinical evidence supports the visual and anatomic improvements observed in the phase 2 STAIRWAY trial indicating that faricimab, driven by its Ang-2 inhibition properties, results in sustained vascular stability, reduced leakage and anti-angiogenic effects, leading to sustained efficacy and durability of treatment effect beyond anti-VEGF monotherapy.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Vogt-Koyanagi-Harada: treatment of recurrence after administration of 3 intravenous bolus of 1g of corticosteroids and mycophenolate mofetil. (Pubmed Central) - Oct 11, 2020
She was diagnosed with incomplete Vogt-Koyanagi-Harada syndrome, and treated early with a combination of intravenous therapy with 1g of prednisolone per day for 3 days, as recommended by published evidence, as well as mycophenolate mofetil (2g per day). During the corticosteroids tapering, there was a recurrence of exudative retinal detachments, and megadoses of 1g of intravenous corticosteroids per day were reintroduced for 6 days until the complete resolution of the fluid of the exudative RD, and cyclosporine (100mg per day), subtenon triamcinolone (40mg/mL), and intravitreal ranibizumab once a month in the both eyes were added to the treatment, with a great control of choroidal inflammation that resulted in the remission of symptoms and signs.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AT 2-MONTH INTERVALS REDUCES FOVEAL AVASCULAR ZONE ENLARGEMENT AND VISION LOSS IN RADIATION MACULOPATHY: A Pilot Study. (Pubmed Central) - Oct 11, 2020
During the corticosteroids tapering, there was a recurrence of exudative retinal detachments, and megadoses of 1g of intravenous corticosteroids per day were reintroduced for 6 days until the complete resolution of the fluid of the exudative RD, and cyclosporine (100mg per day), subtenon triamcinolone (40mg/mL), and intravitreal ranibizumab once a month in the both eyes were added to the treatment, with a great control of choroidal inflammation that resulted in the remission of symptoms and signs. Decrease in best-corrected visual acuity and FAZ enlargement on optical coherence tomography angiography occurred over 6 months in eyes with radiation maculopathy and were significantly reduced under 2-month-interval anti-vascular endothelial growth factor therapy.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results. (Pubmed Central) - Oct 10, 2020
Decrease in best-corrected visual acuity and FAZ enlargement on optical coherence tomography angiography occurred over 6 months in eyes with radiation maculopathy and were significantly reduced under 2-month-interval anti-vascular endothelial growth factor therapy. The deterioration of the macular function on the occluded side during the maintenance phase suggests that there is a progression of the disease process during the PRN period in eyes with BRVOME.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: CoRaLa II: Combination of Ranibizumab and Targeted Laser Photocoagulation (clinicaltrials.gov) - Oct 7, 2020
P3, N=110, Recruiting,
The deterioration of the macular function on the occluded side during the maintenance phase suggests that there is a progression of the disease process during the PRN period in eyes with BRVOME. Not yet recruiting --> Recruiting
|
